Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


We employ our advanced, specialised process to create targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
Q9NSY1

UPID:
BMP2K_HUMAN

ALTERNATIVE NAMES:
-

ALTERNATIVE UPACC:
Q9NSY1; O94791; Q4W5H2; Q8IYF2; Q8N2G7; Q8NHG9; Q9NTG8

BACKGROUND:
The BMP-2-inducible protein kinase, known for its potential involvement in osteoblast differentiation, represents a key player in the regulation of bone development. The protein, identified by the unique identifier Q9NSY1, is essential for understanding the complex mechanisms underlying bone growth and repair.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of BMP-2-inducible protein kinase offers promising avenues for therapeutic intervention. Given its significant role in the differentiation of osteoblasts, targeting this protein could lead to innovative approaches in treating bone-related conditions and enhancing bone regeneration.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.